PCa Commentary - nmCRPC and Androgen Receptor Inhibition: Enzalutamide, Apalutamide and Darolutamide

In volume 171 of his monthly PCa Commentary series, Edward Weber, MD, looks at data on treatment regimens combining enzalutamide, apalutamide, or darolutamide with androgen deprivation in prolonging metastases-free and overall survival in men with nmCRPC who are at high risk for recurrence compared to ADT alone, as well as advantages of PSMA/PET over conventional imaging. To read the Commentary in full, visit our website: https://grandroundsinurology.com/pca-...